Autobio Diagnostics redeems idle funds, profits from cash management

Autobio Diagnostics redeemed 31 million yuan from cash management products in June and July 2025, generating 1.3 million yuan in investment income. The products included a 10 million yuan large-denomination time deposit from Pudong Development Bank, 10 million yuan in treasury bond repurchases from Merchants Securities, and 10 million yuan in income certificates from Shenwan Hongyuan Securities. The principal and income have been returned to the company's raised funds account.

The company's board of directors approved the use of idle raised funds for cash management on December 11, 2024. This allows the company to invest up to 170 million yuan from public convertible bonds and up to 1.7 billion yuan from non-public stock offerings in low-risk, high-liquidity, principal-guaranteed products for a period not exceeding 12 months. This initiative aims to preserve and enhance the value of the raised funds while ensuring no impact on ongoing investment projects.

As of June 30, 2025, Autobio Diagnostics' 2020 non-public offering stock raised funds investment projects had a cumulative investment of 1.17 billion yuan. The cash management activities are not expected to hinder the progress of these projects and aim to generate additional returns for shareholders.